A Phase 2 interventional study of ALLO-647 and Fludarabine in Relapsed/Refractory Large B Cell Lymphoma, sponsored by Allogene Therapeutics. Terminated at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Allogene Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies testing fludarabine in Lymphoma — 8 open to participants now, 13 under way, none of them phase 3. fludarabine · Lymphoma.
Among the 106 studies testing fludarabine in Lymphoma, this one is the 92nd largest by enrollment of the 103 interventional ones that give a count, is one of 3 that started in 2023, is one of 55 in phase 2, and was the 99th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →8 of the 106 studies testing fludarabine in Lymphoma are open now, in 2 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages up to 26
Essen Biotech · Sites in China
Ages 8–85
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
Affiliated Hospital of Nantong University · Sites in China
Ages 18–70
The Affiliated People's Hospital of Ningbo University · Sites in China
Ages 18–75
By country, each count listing its studies:
fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 70 · Phase 3 4 · Phase 4 1
First in 1998; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 31 across the 103 interventional studies. Of the 77 that completed or were terminated, 49 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 106 have an industry lead sponsor. The 10 most frequent:
Allogene Therapeutics is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Allogene Therapeutics has 3 studies filed under Lymphoma — fewer than ten, so there is no comparison to draw.
1 of the studies testing fludarabine in Lymphoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06986434Affiliated Hospital to Academy of Military Medical SciencesCAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation | 2027-05-22 |
Add it to your calendar (.ics) → With an account.
Among the 106 studies testing fludarabine in Lymphoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the EXPAND study is to assess the safety and clinical efficacy of ALLO-647 combined with fludarabine and cyclophosphamide compared to fludarabine and cyclophosphamide alone in a lymphodepletion regimen prior to ALLO-501A CAR T therapy in adults with relapsed or refractory large B-cell lymphoma
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
This study's enrollment of 2 is below the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Browse Lymphoma studies →Allogene Therapeutics is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Compared within Lymphoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALLO-501A CAR T cells infused following lymphodepletion
Biological: ALLO-647 · Drug: Fludarabine · Drug: Cyclophosphamide · Genetic: ALLO-501A
ALLO-501A CAR T cells infused following lymphodepletion
Drug: Fludarabine · Drug: Cyclophosphamide · Genetic: ALLO-501A
ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
Chemotherapy for lymphodepletion
Chemotherapy for lymphodepletion
ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
Progression-Free Survival (PFS) of a Lymphodepletion Regimen Containing FCA vs FC Alone Per Independent Review Committee
To assess the clinical efficacy of ALLO-647 (in a lymphodepletion regimen before ALLO-501A) compared to FC alone as measured by PFS and assessed by Independent Review Committee (IRC) in subjects with R/R (Relapsed / Refractory) LBCL (Large B Cell Lymphoma). In this study, PFS is defined as the time from randomization to disease progression, or relapse per the Lugano classification criteria (Cheson et al, 2014) as assessed by IRC or death.
Time frame: Up to 60 months
Overall-response Rate (ORR) of a Lymphodepletion Regimen Containing FCA vs FC Per Independent Review Committee
To assess the clinical efficacy of ALLO-647 as measured by ORR and assessed by Independent Review Committee (IRC) between treatment arms. ORR is defined as best overall response (Complete Response and Partial Response, assessed using the Lugano classification criteria 2014; Cheson , et al, 2014) by IRC at any time up through commencement of new anti-cancer therapy or withdrawal of consent.
Time frame: Up to 60 months
Event-Free-Survival (EFS) of a Lymphodepletion Regimen Containing FCA vs FC Per Independent Review Committee
To assess clinical efficacy of ALLO-647 with FC (in a lymphodepletion regimen before ALLO-501A) compared to FC alone as measured by Event-Free Survival (EFS) and assessed by Independent Review Committee (IRC) in subjects with R/R LBCL. EFS is defined as the time from randomization to disease progression or relapse per the Lugano classification criteria 2014 as assessed by IRC, new anti-cancer therapy, or death.
Time frame: Up to 60 months
Duration of Response (DOR) of a Lymphodepletion Regimen Containing FCA vs FC Per Independent Review Committee
To characterize the efficacy of ALLO-647 as measured by Duration of Response (DOR) and assessed by Independent Review Committee (IRC) between treatment arms. DOR is defined as time from the first observed response to disease progression or relapse (per IRC) or death.
Time frame: Up to 60 months
Overall Survival (OS) of a Lymphodepletion Regimen Containing FCA vs FC
To characterize the efficacy of ALLO-647 as measured by OS, defined as the time from randomization to death.
Time frame: Up to 60 months, study completion, or death, whichever occurs earlier. Specifically, OS was followed for 4.5 and 10.09 months for each participant in the FCA and FC arm, respectively.
Duration of Response, Event-Free Survival and Progression-Free Survival of a Lymphodepletion Regimen Containing FCA vs FC Based on Response Assessment Per Investigator Review
To characterize the efficacy of ALLO-647 as measured by response rate per investigator, Duration of Response (DOR), Event-Free Survival (EFS), Progression-Free Survival (PFS), assessed by investigator assessments between treatment arms. DOR is defined as time from the first observed response to disease progression or relapse per investigator assessment, or death. EFS is defined as the time from randomization to disease progression or relapse per investigator assessment per the Lugano classification criteria, new anti-cancer therapy, or death. PFS is defined as time from the randomization to progression or relapse per investigator assessment per the Lugano classification criteria, or death.
Time frame: Neither participant was a responder, therefore DOR was not followed. EFS and PFS were followed from first dose of study treatment until disease progression, subsequent anticancer therapy, or death. EFS and PFS were followed for 0.99 to 1.84 months.
Overall Response Rate of a Lymphodepletion Regimen Containing FCA vs FC Based on Response Assessment Per Investigator Review
To characterize the efficacy of ALLO-647 as measured by response rate per investigator, Overall Response Rate (ORR), and assessed by investigator assessments between treatment arms. ORR in FCA vs FC alone per investigator assessment at any time up through commencement of new anti-cancer therapy or withdrawal of consent.
Time frame: Overall Response Rate was followed until disease progression or subsequent anticancer therapy, whichever occurred earlier. Specifically, ORR was followed for 0.99 to 1.84 months for each participant in the FCA and FC arm, respectively.
Depth and Duration of a Lymphodepletion Regimen Containing FCA vs FC
To characterize the depth and duration of lymphodepletion with and without ALLO-647, as assessed by lymphocyte count.
Time frame: From study treatment to study discontinuation, death, withdrawal of consent, or date of initiation of another anticancer therapy, whichever occurs first, for a maximum of 9 months. Only Day 28 lymphocyte counts are available for both participants.
Incidence of Treatment-Emergent Adverse Events (TEAEs)
To evaluate the overall safety profile of ALLO-647 by comparing FCA lymphodepletion with FC lymphodepletion.
Time frame: Up to 60 months, study completion, or death, whichever occurs earlier. TEAEs were followed for 4.5 and 10.09 months for each participant in the FCA and FC arm, respectively.
Incidence of ALLO-501A Related Treatment Emergent Adverse Events
To evaluate the overall safety profile of ALLO-501A following lymphodepletion.
Time frame: Up to 60 months, study completion, or death, whichever occurs earlier. Related TEAEs were followed for 4.5 and 10.09 months for each participant in the FCA and FC arm, respectively.
The study enrolled participants from the United States and Europe. The informed consent date of the first participant was 01 November 2023, and the informed consent date of the last participant was 04 December 2023. The study was terminated prior to completion for business reasons, not due to safety or efficacy concerns.
| Milestone | Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA) | Lymphodepletion With Fludarabine, and Cyclophosphamide (FC) |
|---|---|---|
| Started | 1 | 1 |
| Completed | 0 | 0 |
| Not completed | 1 | 1 |
| Withdrew: Death | 1 | 1 |
To assess the clinical efficacy of ALLO-647 (in a lymphodepletion regimen before ALLO-501A) compared to FC alone as measured by PFS and assessed by Independent Review Committee (IRC) in subjects with R/R (Relapsed / Refractory) LBCL (Large B Cell Lymphoma). In this study, PFS is defined as the time from randomization to disease progression, or relapse per the Lugano classification criteria (Cheson et al, 2014) as assessed by IRC or death.
No measurements were reported for this outcome.
To assess the clinical efficacy of ALLO-647 as measured by ORR and assessed by Independent Review Committee (IRC) between treatment arms. ORR is defined as best overall response (Complete Response and Partial Response, assessed using the Lugano classification criteria 2014; Cheson , et al, 2014) by IRC at any time up through commencement of new anti-cancer therapy or withdrawal of consent.
| Participants | Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA) | Lymphodepletion With Fludarabine, and Cyclophosphamide (FC) |
|---|---|---|
| Overall-response Rate (ORR) of a Lymphodepletion Regimen Containing FCA vs FC Per Independent Review Committee | 0 | 0 |
To assess clinical efficacy of ALLO-647 with FC (in a lymphodepletion regimen before ALLO-501A) compared to FC alone as measured by Event-Free Survival (EFS) and assessed by Independent Review Committee (IRC) in subjects with R/R LBCL. EFS is defined as the time from randomization to disease progression or relapse per the Lugano classification criteria 2014 as assessed by IRC, new anti-cancer therapy, or death.
No measurements were reported for this outcome.
To characterize the efficacy of ALLO-647 as measured by Duration of Response (DOR) and assessed by Independent Review Committee (IRC) between treatment arms. DOR is defined as time from the first observed response to disease progression or relapse (per IRC) or death.
No measurements were reported for this outcome.
To characterize the efficacy of ALLO-647 as measured by OS, defined as the time from randomization to death.
| Months | Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA) | Lymphodepletion With Fludarabine, and Cyclophosphamide (FC) |
|---|---|---|
| Overall Survival (OS) of a Lymphodepletion Regimen Containing FCA vs FC | 4.50 (4.50 to 4.50) | 10.09 (10.09 to 10.09) |
To characterize the efficacy of ALLO-647 as measured by response rate per investigator, Duration of Response (DOR), Event-Free Survival (EFS), Progression-Free Survival (PFS), assessed by investigator assessments between treatment arms. DOR is defined as time from the first observed response to disease progression or relapse per investigator assessment, or death. EFS is defined as the time from randomization to disease progression or relapse per investigator assessment per the Lugano classification criteria, new anti-cancer therapy, or death. PFS is defined as time from the randomization to progression or relapse per investigator assessment per the Lugano classification criteria, or death.
| Months | Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA) | Lymphodepletion With Fludarabine, and Cyclophosphamide (FC) |
|---|---|---|
| Progression-Free Survival | 0.99 (0.99 to 0.99) | 1.84 (1.84 to 1.84) |
| Event-Free Survival | 0.99 (0.99 to 0.99) | 1.84 (1.84 to 1.84) |
To characterize the efficacy of ALLO-647 as measured by response rate per investigator, Overall Response Rate (ORR), and assessed by investigator assessments between treatment arms. ORR in FCA vs FC alone per investigator assessment at any time up through commencement of new anti-cancer therapy or withdrawal of consent.
| Participants | Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA) | Lymphodepletion With Fludarabine, and Cyclophosphamide (FC) |
|---|---|---|
| Overall Response Rate of a Lymphodepletion Regimen Containing FCA vs FC Based on Response Assessment Per Investigator Review | 0 | 0 |
To characterize the depth and duration of lymphodepletion with and without ALLO-647, as assessed by lymphocyte count.
| cells/cubic millimeter | Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA) | Lymphodepletion With Fludarabine, and Cyclophosphamide (FC) |
|---|---|---|
| Depth and Duration of a Lymphodepletion Regimen Containing FCA vs FC | 300 (300 to 300) | 417 (417 to 417) |
To evaluate the overall safety profile of ALLO-647 by comparing FCA lymphodepletion with FC lymphodepletion.
| Participants | Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA) | Lymphodepletion With Fludarabine, and Cyclophosphamide (FC) |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events (TEAEs) | 1 | 1 |
To evaluate the overall safety profile of ALLO-501A following lymphodepletion.
| Participants | Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA) | Lymphodepletion With Fludarabine, and Cyclophosphamide (FC) |
|---|---|---|
| Incidence of ALLO-501A Related Treatment Emergent Adverse Events | 1 | 0 |
Collected over From participant's first dose date of any study drug up to 60 months post ALLO-647 infusion, date of death, date of study discontinuation, or the date of initiation of another anti-cancer agent, whichever occurs first; follow up of the participants ended within 11 months after ALLO-501A infusion due to death as a result of disease progression.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Lymphodepletion With Fludarabine, and Cyclophosphamide (FC) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Event | Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA) | Lymphodepletion With Fludarabine, and Cyclophosphamide (FC) |
|---|---|---|
| Sinus TachycardiaCardiac disorders | 1/1 | 0/1 |
| FatigueGeneral disorders | 1/1 | 0/1 |
| FallInjury, poisoning and procedural complications | 1/1 | 0/1 |
| Electrocardiogram QT prolongedInvestigations | 1/1 | 0/1 |
| HyponatremiaMetabolism and nutrition disorders | 1/1 | 0/1 |
| HypokalemiaMetabolism and nutrition disorders | 1/1 | 0/1 |
| HypophosphataemiaMetabolism and nutrition disorders | 1/1 | 0/1 |
| Tumor lysis syndromeMetabolism and nutrition disorders | 1/1 | 0/1 |
| DysgeusiaNervous system disorders | 1/1 | 0/1 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/1 | 0/1 |
| Age, Categorical(Participants) | Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA) | Lymphodepletion With Fludarabine, and Cyclophosphamide (FC) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 1 | 2 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA) | Lymphodepletion With Fludarabine, and Cyclophosphamide (FC) | Total |
|---|---|---|---|
| Female | NA | NA | NA |
| Male | NA | NA | NA |
| Race (NIH/OMB)(Participants) | Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA) | Lymphodepletion With Fludarabine, and Cyclophosphamide (FC) | Total |
|---|---|---|---|
| American Indian or Alaska Native | NA | NA | NA |
| Asian | NA | NA | NA |
| Native Hawaiian or Other Pacific Islander | NA | NA | NA |
| Black or African American | NA | NA | NA |
| White | NA | NA | NA |
| More than one race | NA | NA | NA |
| Unknown or Not Reported | NA | NA | NA |
| Ethnicity (NIH/OMB)(Participants) | Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA) | Lymphodepletion With Fludarabine, and Cyclophosphamide (FC) | Total |
|---|---|---|---|
| Hispanic or Latino | NA | NA | NA |
| Not Hispanic or Latino | NA | NA | NA |
| Unknown or Not Reported | NA | NA | NA |
| Region of Enrollment(Participants) | Lymphodepletion With Fludarabine, Cyclophosphamide, and ALLO-647 (FCA) | Lymphodepletion With Fludarabine, and Cyclophosphamide (FC) | Total |
|---|---|---|---|
| United States | 1 | 0 | 1 |
| Belgium | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2023 to primary completion in Feb 2024, 3 months.
Results were first posted in Dec 2025, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fludarabine · Cyclophosphamide
Allogene Therapeutics